Clinical pharmacology of 5-hydroxytryptamine and catecholamines venomotor receptors.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000605:Amino Alcohols / Q000494:pharmacology; D002395:Catecholamines / Q000494:pharmacology*; D004336:Drug Antagonism; D004347:Drug Interactions; D004357:Drug Synergism; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D007545:Isoproterenol / Q000494:pharmacology; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects*; D009578:Nitrobenzenes / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010627:Phenethylamines / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011941:Receptors, Adrenergic / Q000187:drug effects; D011955:Receptors, Drug / Q000187:drug effects*; D012701:Serotonin / Q000494:pharmacology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology; D014680:Veins / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D002395:Catecholamines; D009578:Nitrobenzenes; D010627:Phenethylamines; D011941:Receptors, Adrenergic; D011955:Receptors, Drug; D014662:Vasoconstrictor Agents; D012701:Serotonin; D008238:Lysergic Acid Diethylamide; D007545:Isoproterenol; D009638:Norepinephrine; D004837:Epinephrine; D010646:Phentolamine